ORKA-001 Maintenance Dose
Phase 2
ORKA-001 Maintenance Dose is one of 9 therapeutic programs targeting Plaque Psoriasis. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
8
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
13 competitors in Plaque Psoriasis
#DrugCompanyPhaseTrials
1Otezla
AmgenPhase 3
Sotyktu
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
JNJ-77242113
Johnson & JohnsonPhase 3
Envudeucitinib
AAlumis Inc
Phase 3
ORKA-002
OOruka Therapeutics, Inc.
Phase 2
ESK-001
AAlumis Inc
Phase 2
ORKA-001
OOruka Therapeutics, Inc.
Phase 2
ORKA-001 Maintenance Dose
OOruka Therapeutics, Inc.
Phase 2
ZP9830
Zealand PharmaPhase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Plaque Psoriasis1 trial
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for ORKA-001 Maintenance Dose. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 2[1]
- Company
- OOruka Therapeutics, Inc.